276 related articles for article (PubMed ID: 28425346)
1. Ambrisentan: a review of its use in pulmonary arterial hypertension.
Rivera-Lebron BN; Risbano MG
Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
[TBL] [Abstract][Full Text] [Related]
2. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
3. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
4. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
[TBL] [Abstract][Full Text] [Related]
5. Ambrisentan (Letairis) and tadalafil (Adcirca) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2016 Jan; 58(1485):2-4. PubMed ID: 26714240
[No Abstract] [Full Text] [Related]
6. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Vizza CD; Fedele F; Pezzuto B; Rubin LJ
Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
[TBL] [Abstract][Full Text] [Related]
9. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
Hoeper MM; McLaughlin VV; Barberá JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rosenkranz S; Oudiz RJ; White RJ; Miller KL; Langley J; Harris JHN; Blair C; Rubin LJ; Vachiery JL
Lancet Respir Med; 2016 Nov; 4(11):894-901. PubMed ID: 27745818
[TBL] [Abstract][Full Text] [Related]
10. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Vachiéry JL; Galiè N; Barberá JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Blair C; Miller KL; Langley J; Rubin LJ;
J Heart Lung Transplant; 2019 Feb; 38(2):194-202. PubMed ID: 30522722
[TBL] [Abstract][Full Text] [Related]
11. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
[TBL] [Abstract][Full Text] [Related]
13. An update on the use of ambrisentan in pulmonary arterial hypertension.
D'Alto M
Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Issapour A; Frank B; Crook S; Hite MD; Dorn ML; Rosenzweig EB; Ivy DD; Krishnan US
Pediatr Pulmonol; 2022 Mar; 57(3):724-733. PubMed ID: 34921523
[TBL] [Abstract][Full Text] [Related]
15. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
[TBL] [Abstract][Full Text] [Related]
16. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q; Guo N; Chen J; Parks D; Tian Z
J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
[TBL] [Abstract][Full Text] [Related]
18. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
19. Ambrisentan for the management of pulmonary arterial hypertension.
Cheng JW
Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
[TBL] [Abstract][Full Text] [Related]
20. Ambrisentan and its role in the management of pulmonary arterial hypertension.
Macintyre IM; Dhaun N; Goddard J; Webb DJ
Drugs Today (Barc); 2008 Dec; 44(12):875-85. PubMed ID: 19198697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
